Alzinova announces that Mangold Insight initiates equity research coverage of the company
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer’s disease by specifically targeting neurotoxic amyloid-beta oligomers, today announces that Mangold Insight has been engaged by Alzinova to produce regular, in-depth equity research reports on the company.
The primary purpose is to enable investors and stakeholders to develop an improved understanding of the business, as well as raise the visibility of Alzinova.
The initial analysis is now published and is available on Alzinova's website, https://www.alzinova.com/investors/the-share/analyst-coverage/, as well as on Mangold Insights website, https://mangold.se/mangold-insight/.
For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:16 a.m. CET on January 26, 2022.
About Mangold Insight
Mangold Insight is Mangold Fondkommission's commissioned analysis service whose purpose is to contribute to new investor perspectives and raise the stock market's eyes for small and medium growth companies listed on the trading venues Spotlight Stockmarket, NGM, Nasdaq First North Growth Market and Nasdaq Stockholm. The assignment analyses can then be accessed by investors free of charge and without membership via Mangold Insight's website https://mangold.se/mangold-insight/.
About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in early preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com